COLL logo

COLL
Collegium Pharmaceutical Inc

1,590
Mkt Cap
$1.09B
Volume
344,422.00
52W High
$50.79
52W Low
$26.72
PE Ratio
19.99
COLL Fundamentals
Price
$34.32
Prev Close
$33.73
Open
$33.79
50D MA
$35.86
Beta
0.57
Avg. Volume
488,568.48
EPS (Annual)
$1.73
P/B
3.61
Rev/Employee
$1.85M
$2,368.09
Loading...
Loading...
News
all
press releases
Earnings Preview: Collegium Pharmaceutical (COLL) Q1 Earnings Expected to Decline
Collegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·2d ago
News Placeholder
More News
News Placeholder
Collegium Pharmaceutical (COLL) to Release Quarterly Earnings on Thursday
Collegium Pharmaceutical (NASDAQ:COLL) will be releasing its Q1 2026 earnings before the market opens on Thursday, May 7. (View Earnings Report at...
MarketBeat·2d ago
News Placeholder
Q1 EPS Estimate for Collegium Pharmaceutical Cut by Analyst
Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) - Investment analysts at HC Wainwright lowered their Q1 2026 earnings estimates for Collegium Pharmaceutical in a research note issued on...
MarketBeat·5d ago
News Placeholder
Equities Analysts Offer Predictions for COLL Q2 Earnings
Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) - Equities research analysts at HC Wainwright dropped their Q2 2026 earnings per share (EPS) estimates for Collegium Pharmaceutical in a...
MarketBeat·8d ago
News Placeholder
Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Receives Average Recommendation of "Moderate Buy" from Brokerages
Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the seven research firms that are presently covering the stock...
MarketBeat·11d ago
News Placeholder
Collegium Pharmaceutical (NASDAQ:COLL) Stock Price Down 4.6% - Here's What Happened
Collegium Pharmaceutical (NASDAQ:COLL) Trading Down 4.6% - Here's Why...
MarketBeat·16d ago
News Placeholder
Collegium Pharmaceutical Sets 2026 Revenue Outlook, Details $650M AZSTARYS Deal at Needham Conference
Collegium Pharmaceutical (NASDAQ:COLL) outlined its 2026 outlook and discussed its planned acquisition of the ADHD treatment AZSTARYS during a fireside chat at Needham & Company's 25th Annual...
MarketBeat·16d ago
News Placeholder
Massachusetts Financial Services Co. MA Increases Stock Position in Collegium Pharmaceutical, Inc. $COLL
Massachusetts Financial Services Co. MA grew its stake in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 65.3% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,312,655 shares of...
MarketBeat·17d ago
News Placeholder
Collegium Pharmaceutical (NASDAQ:COLL) Stock Price Crosses Below Fifty Day Moving Average - Should You Sell?
Collegium Pharmaceutical (NASDAQ:COLL) Stock Crosses Below Fifty Day Moving Average - Here's Why...
MarketBeat·22d ago
News Placeholder
JPMorgan Chase & Co. Acquires 139,689 Shares of Collegium Pharmaceutical, Inc. $COLL
JPMorgan Chase & Co. boosted its holdings in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 193.8% in the third quarter, according to the company in its most recent 13F...
MarketBeat·1mo ago
<
1
2
...
>

Latest COLL News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.